Q4 Earnings Forecast for Annovis Bio Issued By HC Wainwright

Annovis Bio, Inc. (NYSE:ANVS - Free Report) - Equities researchers at HC Wainwright reduced their Q4 2024 earnings per share estimates for Annovis Bio in a note issued to investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.38) per share for the quarter, down from their previous forecast of ($0.30). HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for Annovis Bio's current full-year earnings is ($1.99) per share. HC Wainwright also issued estimates for Annovis Bio's Q1 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.76) EPS and FY2025 earnings at ($2.32) EPS.

Annovis Bio (NYSE:ANVS - Get Free Report) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.33).

ANVS has been the subject of several other reports. EF Hutton Acquisition Co. I upgraded shares of Annovis Bio to a "strong-buy" rating in a report on Tuesday, August 13th. Maxim Group raised Annovis Bio from a "hold" rating to a "buy" rating and set a $25.00 target price for the company in a report on Friday, October 25th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Annovis Bio currently has a consensus rating of "Buy" and an average price target of $32.17.

Annovis Bio Trading Down 5.9 %

NYSE ANVS traded down $0.44 on Thursday, hitting $6.97. 245,173 shares of the company's stock were exchanged, compared to its average volume of 766,348. Annovis Bio has a 52 week low of $4.53 and a 52 week high of $22.49. The stock has a 50-day moving average of $8.47 and a 200-day moving average of $8.27. The stock has a market cap of $96.19 million, a price-to-earnings ratio of -1.66 and a beta of 1.70.

Institutional Trading of Annovis Bio

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC purchased a new position in shares of Annovis Bio in the 3rd quarter worth about $371,000. Greenwich Wealth Management LLC raised its position in Annovis Bio by 9.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 16,475 shares of the company's stock worth $133,000 after purchasing an additional 1,400 shares during the period. XTX Topco Ltd bought a new stake in Annovis Bio in the second quarter worth $115,000. Cetera Advisors LLC purchased a new stake in Annovis Bio during the first quarter valued at about $122,000. Finally, Vanguard Group Inc. grew its stake in shares of Annovis Bio by 6.1% during the first quarter. Vanguard Group Inc. now owns 357,942 shares of the company's stock valued at $4,260,000 after buying an additional 20,588 shares during the last quarter. 15.83% of the stock is currently owned by hedge funds and other institutional investors.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.